Background: Sleep efficiency of <80% based on actigraphy was defined as insomnia as self-reported difficulty falling asleep or waking up at night three to four times per week. It is known that adequate sleep is very important for human wellbeing, affecting people's work and life, insomnia will seriously damage our daily life. There is no recognized non-drug treatment. Studies have found that Taijiquan has a positive effect on insomnia patients. This systematic review and meta-analysis will evaluate the effect of Taijiquan on insomnia.Methods: To find all randomized controlled trials exploring the effects of Taijiquan on insomnia patients in Chinese and English, eight databases (Pubmed, Embase, Cochrane library, Web of Science, CNKI, CBM, VIP, and Wanfang Data) were searched. The retrieval time is from database construction to October 2021. Searches were conducted in both English and Chinese language. A meta-analysis by mean difference (MD) and 95% confidence interval (CI) was performed with RevMan 5.3. The risk of bias for each study was accounted for according to the Cochrane Handbook. Our primary outcome was Pittsburg Sleep Quality Index. We explored sources of heterogeneity by comparing effect sizes across different types of etiology, country, control group, and intervention type. The protocol was pre-registered with PROSPERO, CRD42021284511.Results: Twenty-one RCTs published between 2004 and 2021 with 2,022 participants were included in this study. Twenty-one randomized controlled studies showed that Tai Chi significantly improved PSQI scores in patients with cancer, muscle fibrosis, and sub-health insomnia [MD = −1.16, 95% CI (−1.62, −0.71), P < 0.01]; There is insufficient evidence of improvement in patients with cerebrovascular disease [MD = −0.54, 95% CI (−1.58, 0.51), P = 0.31]; 8-form, 10-form or 24-form Yang's Taijiquan had the same effect in improving PSQI [MD = −1.33, 95% CI (−1.85, −0.81), P < 0.01]. When there is no treatment, exercise, exercise and health education as the control, taijiquan has a significant effect on insomnia treatment, and there is no difference in efficacy compared with cognitive behavioral therapy and health education (usual care) alone.Conclusions: The results of the study showed that Taijiquan significantly improved sleep quality in healthy adults and patients with chronic diseases, which suggests that Taijiquan may be considered as an alternative behavioral therapy in the treatment of insomnia. In the future, more high-quality, well-controlled randomized trials are needed to better inform clinical decisions.

Paclitaxel induced fatigue still remains underrecognized and undertreated, partly because of limited understanding of its pathophysiology and lack of effective treatments. This study is aim to evaluate the anti-fatigue effects and mechanism of Bu-Zhong-Yi-Qi pill in murine 4 T1 breast cancer mice were treated with paclitaxel. Breast cancer mice established with murine 4 T1 cells were randomly and repectively divided into five groups: negative control group (NC), tumor control group (TC), paclitaxel group (PTX), Bu-Zhong-Yi-Qi pill group (BZYQ) and Bu-Zhong-Yi-Qi pill plus paclitaxel group (BZYQ + PTX). The mice were administered for 21 days. During this period, the tumor volume, body weight and the weight-loaded swimming time were measured. After the last administration, all mice were sacrificed, weighted the tumor, measured immune cell cytokines and oxidative stress indicator. The remaining 10 mice in each group were observed for survival analysis. Treatments with BZYQ + PTX and PTX significantly reduced the rates of tumor volume in comparison with TC starting on the 9th day and the 18th day respectively (P < 0.05-0.01), and presented decreased tumor weight compared to TC (P < 0.05-0.01). Compared with mice in TC group, the median survival time and the average survival time in BZYQ + PTX group, BZYQ group and PTX group were significantly prolonged (P < 0.05-0.01). The swimming time of the BZYQ + PTX group gradually increased, which is longer than the PTX group on Day 14 and Day 21 (P < 0.01). The level of TNF-α was lower in BZYQ + PTX group than PTX group (P < 0.01). The level of SOD activity in BZYQ + PTX group was lower than the NC group (P <0.01), but much higher than the PTX group (P < 0.01). The level of MDA of BZYQ + PTX group was higher than the NC group (P < 0.01), but significant lower than the PTX group (P < 0.01). BZYQ has the potential of alleviating paclitaxel chemotherapy-related fatigue in 4 T1 breast cancer mice by reducing the serum levels of TNF-α and modulating the level of MDA and the SOD activity.

Macrophages and microglia serve as both "scavengers" and "immune sentinels" to maintain tissue homeostasis. However, when the lipid load exceeds their processing capacity, these cells transform into foam cells, thereby driving chronic inflammation and impairing tissue repair. Despite their distinct organ systems, atherosclerosis (AS) and spinal cord injury (SCI) converge on a common pathological cascade-foam cell formation-characterized by "enhanced lipid uptake, impaired cholesterol efflux, disrupted lysosomal/autophagic processing, and ER stress/ROS/NLRP3-mediated inflammatory amplification." This review systematically dissects and compares the molecular mechanisms underlying macrophage foaming in AS and SCI, with a particular focus on the similarities and differences in ABCA1/ABCG1-mediated cholesterol efflux, lipid droplet autophagy, the ER stress-NLRP3 axis, and nuclear receptor regulatory networks. Furthermore, it explores therapeutic avenues that target lipid metabolic reprogramming, including natural products, biomimetic nanomedicines, and genetic interventions. By establishing a cross-disease framework for lipid homeostasis disruption, this paper challenges traditional organ-centric views and provides a theoretical foundation that may accelerate the development of shared therapeutic strategies for AS and SCI.

Platelet-rich plasma (PRP), an autologous blood derivative rich in multiple growth factors and cytokines, has shown broad application prospects in the field of tissue repair and regeneration. In recent years, the therapeutic potential of PRP in neurological disorders has gained increasing attention. This article systematically reviews the classification systems, preparation methods, and the molecular mechanisms and application progress of PRP in neural repair. In preclinical studies, PRP has been shown to release insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-β (TGF-β), which may synergistically activate PI3K/Akt and MAPK/ERK signaling pathways, suggesting potential tissue repair, axonal regenerative, angiogenic, and immunomodulatory effects. The three-dimensional fibrin scaffold formed upon platelet activation not only provides physical support for cell migration and axonal growth but also enables the sustained local release of growth factors. In central nervous system disorders, intrathecal PRP has shown potential in animal models to alleviate neuroinflammation after spinal cord injury(SCI), and intranasal administration can improve cognitive function and neurogenesis in Alzheimer’s disease(AD) models. In peripheral nervous system disorders, local injection or PRP filling within nerve conduits significantly promotes regeneration and functional recovery after injuries to the sciatic nerve, facial nerve, and others. Furthermore, the therapeutic efficacy of PRP is influenced by factors such as preparation method, cellular composition (leukocyte content), administration route, and activation method. Although preclinical evidence is substantial, the clinical application of PRP in neurological disorders still faces challenges including a lack of standardization, unclear mechanisms, and the need to verify long-term safety. This review aims to provide a theoretical basis and practical reference for further research and clinical translation of PRP in the field of neural repair.